[go: up one dir, main page]

MX2016010995A - Novedoso anticuerpo anti-presepsina. - Google Patents

Novedoso anticuerpo anti-presepsina.

Info

Publication number
MX2016010995A
MX2016010995A MX2016010995A MX2016010995A MX2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A MX 2016010995 A MX2016010995 A MX 2016010995A
Authority
MX
Mexico
Prior art keywords
antibody
presepsin
novel anti
presepsin antibody
antigen
Prior art date
Application number
MX2016010995A
Other languages
English (en)
Other versions
MX375897B (es
Inventor
Shirakawa Kamon
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of MX2016010995A publication Critical patent/MX2016010995A/es
Publication of MX375897B publication Critical patent/MX375897B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención aborda el problema de proporcionar un nuevo anticuerpo monoclonal que tiene una excelente reactividad con presepsina y es adecuado para medir presepsina en una muestra, o un fragmento de anticuerpo de unión a un antígeno de dicho anticuerpo. Se proporciona un anticuerpo anti-presepsina que reconoce específicamente un epítopo que comprende una SEC ID NO: 1 secuencia de aminoácido, o un fragmento de anticuerpo de unión a un antígeno de dicho anticuerpo.
MX2016010995A 2014-02-26 2015-02-25 Novedoso anticuerpo anti-presepsina. MX375897B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461944674P 2014-02-26 2014-02-26
PCT/JP2015/055488 WO2015129774A1 (ja) 2014-02-26 2015-02-25 新規抗プレセプシン抗体

Publications (2)

Publication Number Publication Date
MX2016010995A true MX2016010995A (es) 2017-02-27
MX375897B MX375897B (es) 2025-03-07

Family

ID=53881586

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010995A MX375897B (es) 2014-02-26 2015-02-25 Novedoso anticuerpo anti-presepsina.

Country Status (18)

Country Link
US (3) US9951142B2 (es)
EP (2) EP3628731B1 (es)
JP (4) JP6567496B2 (es)
KR (1) KR102360851B1 (es)
CN (1) CN106255751B (es)
AU (1) AU2015223840B2 (es)
BR (1) BR112016019739B1 (es)
CA (1) CA2938956C (es)
ES (2) ES2753400T3 (es)
LT (1) LT3628731T (es)
MX (1) MX375897B (es)
NZ (1) NZ722440A (es)
PH (1) PH12016501579B1 (es)
PL (2) PL3628731T3 (es)
RS (2) RS59549B1 (es)
RU (1) RU2710439C2 (es)
SI (1) SI3628731T1 (es)
WO (1) WO2015129774A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106255751B (zh) 2014-02-26 2020-04-10 持田制药株式会社 新的抗普莱晒谱星抗体
US11117974B2 (en) * 2015-08-25 2021-09-14 Mochida Pharmaceutical Co., Ltd. Specifically purified anti-presepsin antibody
CN108680634B (zh) * 2018-08-28 2023-09-08 长沙理工大学 一种基于谷胱甘肽修饰栅极金电极的l-胱氨酸的检测方法及传感器
CN113939314B (zh) * 2019-11-19 2022-09-30 武汉全景生物技术有限公司 新的抗可溶性cd14亚型抗体及其应用
CN113939533B (zh) * 2020-06-18 2022-12-06 武汉全景生物技术有限公司 抗可溶性cd14亚型抗体、试剂盒及其应用
CN113555118B (zh) * 2021-07-26 2023-03-31 内蒙古自治区人民医院 一种病症程度的预测方法、装置、电子设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506580C (en) * 2002-11-12 2010-08-17 Mochida Pharmaceutical Co., Ltd. Assay kit and antibody for human low molecular weight cd14
US7608684B2 (en) * 2002-11-12 2009-10-27 Mochida Pharmaceuticals Co., Ltd. Soluble CD14 antigen
JP2005106694A (ja) * 2003-09-30 2005-04-21 Mochida Pharmaceut Co Ltd 敗血症早期検出及び重篤度評価
CA2566101C (en) * 2004-05-11 2013-05-21 Mochida Pharmaceutical Co., Ltd. Novel soluble cd14 antigen
JP4891125B2 (ja) 2005-06-03 2012-03-07 持田製薬株式会社 抗ｃｄ１４抗体融合蛋白質
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
CA2725144C (en) 2008-05-23 2018-11-06 Mochida Pharmaceutical Co., Ltd. Method for evaluation of function of phagocyte
WO2011093459A1 (ja) * 2010-01-29 2011-08-04 三菱化学メディエンス株式会社 ヒトｓＣＤ１４－ＳＴの分析方法
US20130337476A1 (en) * 2012-06-13 2013-12-19 Min-Yi Lee URINARY sCD14 AS A BIOMARKER FOR CORONARY ARTERY DISEASE
CN106255751B (zh) 2014-02-26 2020-04-10 持田制药株式会社 新的抗普莱晒谱星抗体
US11117974B2 (en) 2015-08-25 2021-09-14 Mochida Pharmaceutical Co., Ltd. Specifically purified anti-presepsin antibody

Also Published As

Publication number Publication date
JP6759429B2 (ja) 2020-09-23
RU2016137807A3 (es) 2018-09-06
CN106255751A (zh) 2016-12-21
US11685788B2 (en) 2023-06-27
JPWO2015129774A1 (ja) 2017-03-30
CA2938956C (en) 2022-04-26
RS62033B1 (sr) 2021-07-30
JP2021003115A (ja) 2021-01-14
WO2015129774A1 (ja) 2015-09-03
BR112016019739B1 (pt) 2023-10-10
JP6567496B2 (ja) 2019-08-28
US10676532B2 (en) 2020-06-09
ES2753400T3 (es) 2020-04-08
AU2015223840B2 (en) 2020-08-13
EP3628731B1 (en) 2021-04-21
EP3112463A1 (en) 2017-01-04
PH12016501579A1 (en) 2016-10-03
JP2023025047A (ja) 2023-02-21
EP3112463A4 (en) 2017-12-13
ES2880225T3 (es) 2021-11-24
EP3112463B1 (en) 2019-09-04
RU2016137807A (ru) 2018-04-02
PH12016501579B1 (en) 2016-10-03
RS59549B1 (sr) 2019-12-31
RU2710439C2 (ru) 2019-12-26
NZ722440A (en) 2023-04-28
AU2015223840A1 (en) 2016-09-08
LT3628731T (lt) 2021-08-10
PL3628731T3 (pl) 2021-11-15
EP3628731A1 (en) 2020-04-01
PL3112463T3 (pl) 2020-03-31
US20210107990A1 (en) 2021-04-15
US9951142B2 (en) 2018-04-24
CA2938956A1 (en) 2015-09-03
KR20170002367A (ko) 2017-01-06
BR112016019739A2 (pt) 2017-10-24
SI3628731T1 (sl) 2021-08-31
KR102360851B1 (ko) 2022-02-09
US20180201688A1 (en) 2018-07-19
US20150239982A1 (en) 2015-08-27
MX375897B (es) 2025-03-07
CN106255751B (zh) 2020-04-10
AU2015223840A2 (en) 2016-09-15
JP2019205458A (ja) 2019-12-05

Similar Documents

Publication Publication Date Title
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
MX377344B (es) Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas.
MX2017001597A (es) Anticuerpos anti-pd-l1.
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
PH12016501212A1 (en) Human anti-il-33 neutralizing monoclonal antibody
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
EA201591465A1 (ru) Специфичные участки для модификации антител для получения иммуноконъюгатов
MX2016010995A (es) Novedoso anticuerpo anti-presepsina.
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
MX366359B (es) Anticuerpos humanizados contra la molecula de adhesion celular relacionada al antigeno carcinoembrionico 1 (ceacam1).
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител
CU24556B1 (es) Anticuerpos anti-basigin humanizados
EA201990673A1 (ru) Антитела, специфически связывающиеся с il-17a, и их функциональные фрагменты
MX2017013333A (es) Metodo para purificacion de proteina.
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
ZA202005023B (en) L2a5 antibody or functional fragment thereof against tumour antigens
SG11201810779PA (en) Method for screening antibody using patient-derived tumor spheroids
BR112018068803A2 (pt) método para purificação de proteína
EA201892313A1 (ru) Гуманизированные антитела против clever-1 и их применение
MX2015017714A (es) Selecciones fenotipicas, descubrimiento del antigeno objetivo y uso de los mismos para la identificacion de epitopes objetivo especificos de celulas objetivo.
MX2019002455A (es) Metodos para la identificacion de epitopes.
EA202090309A1 (ru) Анти-tigit антитела
MX2018004228A (es) Anticuerpo que se une especificamente a erbb3 y uso de este.
PL409845A1 (pl) Przeciwciała poliklonalne klasy IgY specyficzne wobec peptydowego składnika ściany komórkowej bakterii oraz ich zastosowanie

Legal Events

Date Code Title Description
FG Grant or registration